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The Road Ahead*Mona Fiuzat, PHARMD, Norman Stockbridge, MD, Robert M. Califf, MDC ardiovascular (CV) disease remains the lead-ing cause of death in the United States andworldwide, and remains an enormous dis-
ease burden (1). Despite this fact, the investment in
CV drug development has decreased over the past 2
decades relative to other therapeutic areas such as
oncology (2). These trends are concerning and raise
the question of whether regulators, other govern-
ment entities, industry, and academic investigators
should rethink the approach to the science we need
to reduce disease burden in this enormous cause of
global death and disability.SEE PAGE 301In this issue of JACC: Basic to Translational Science,
Hwang et al. (3) demonstrate that the volume of new
drugs entered into cardiovascular clinical trials has
diminished over the past decade relative to many
other ﬁelds. However, the number of novel drugs
entering Phase 3 trials increased over time. Discon-
tinuation of drug development programs was pri-
marily due to inadequate efﬁcacy, and only 24% of
development programs that were discontinued
were stopped due to safety concerns. They use data
from a large commercial database that tracks the
pipeline of pharmaceutical research and development,
examining products entering Phase 1 trials from*Editorials published in JACC: Basic to Translational Science reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Basic to Translational Science or the American College of Cardiology.
From the U.S. Food and Drug Administration, Silver Spring, Maryland.
The authors have reported that they have no relationships relevant to the
contents of this paper to disclose.January 1990 to December 2012, with 4,715 products
meeting this criterion. The most common CV products
being developed were antihypertensive agents, fol-
lowed by lipid-lowering agents and anticoagulant
agents. They found the rate of new CV products
entering Phase I trials diminished from 16% of all
products in development in 1990 to 1995 to just 5% of
all products in development in 2005 to 2012. The
number of actual new starts declined, too, from 18
products/year to 13 products/year over that time
frame. Interestingly, one-half of the drugs entering
Phase 3 were targeting a novel biological pathway,
which is a trend that increased over time (p ¼ 0.004
for linear trend). This is encouraging because it
indicates a priority for truly novel targets in drug
development.
This trend towards less relative investment in CV
drug development has been previously reported, and
a number of issues were addressed in a meeting of
experts convened in 2015 (2). As described in the
summary paper, the issues are multifactorial
including rising drug development costs and percep-
tions about the concept of “regulatory uncertainty.”
The challenge is ﬁnding a balance between the
imperative to generate evidence to ensure that new
drugs entering the market meet a reasonable standard
for safety and effectiveness, yet weighing the burden
of cost and efﬁciency that may push investment in
innovation into other therapeutic areas. There was a
viewpoint that given the large number of beneﬁcial
therapies in CV disease, the stringent requirements
for demonstration of beneﬁt in clinical outcomes,
although justiﬁed, may be pushing drug developers to
areas in which smaller trials with less stringent clin-
ical outcome measurements are required.
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310It has been suggested that we can “reduce regula-
tory uncertainty” (4). But what does this actually
mean? Because the FDA’s mission includes promoting
and protecting the public health by assuring the
safety, efﬁcacy, and security of human drugs, and the
agency is held to a certain evidentiary standard in
approving drugs, simply reducing the sample size or
using unvalidated biomarkers for regulatory decision
making when determining the balance of beneﬁt and
risk has not been a feasible approach for diseases in
which so many effective therapies are already avail-
able. For the large CV diseases and their proximal
risks, there is much to lose if unvalidated putative
surrogates are used, only to be proven invalid after
marketing to millions of patients and their providers.
Indeed, many of the large, failed Phase 3 programs
in CV drug development were supported by sub-
stantial evidence of favorable effect on key bio-
markers that in general have been accepted
surrogates, such as blood pressure, low-density lipo-
protein (LDL) and high-density lipoprotein (HDL)
cholesterol and hemoglobin A1C (5–7). Unfortunately,
in these cases, the beneﬁt predicted by the improve-
ment in the surrogate was not achieved, either
because of lack of efﬁcacy or severe off-target toxicity
when the larger trials have been conducted. Perhaps
we should focus on improving our evidence genera-
tion system so that we can generate reliable evidence
in a more efﬁcient fashion. In this age of dramatic
advances in information technology, there will be a
number of opportunities for generating evidence us-
ing integrated health systems and networks of infor-
mation (8).
It may also be worthwhile to consider the relevant
differences between the development of drugs in
oncology versus cardiovascular therapies. Advances
in cancer biology have led to the dissection of cancer
into many small diseases, and many types of cancer
either have no effective treatment, or initial effective
therapies are just now being discovered. This
dissection leads to some fairly cause-speciﬁc thera-
pies and molecular targets. Because of the paucity of
effective therapies, as targeted therapies are discov-
ered with promise of a very large treatment effect
size, we accept more biomarker-based approval, less
conﬁdence in the evidence of beneﬁt, and higher
uncertainties about safety. We also generally accept
higher demonstrated safety risks, including, ironi-
cally, cardiotoxicity. Thus, development programs in
oncology are generally smaller and less expensive,
and the value placed on targeted therapies has
allowed sponsors to recoup the costs by charging a lot
to a few, although this pricing approach is increas-
ingly under scrutiny.Importantly, the focus of this paper is on cardio-
vascular development in the “big problems” like
“essential” (idiopathic) hypertension and primary
(NOS) hyperlipidemia, and ﬁnal-common-pathway
heart failure—with big populations and multiple
effective therapies already on the market, many of
which are now generic. Currently marketed therapies
are well-described with highly acceptable toxicity
proﬁles, so new therapies must compete with these
well-established therapies, making safety databases
large (routinely about 100-fold as large as it takes to
work up the dose-response on blood pressure). So,
even though treatments for hypertension and lipids
have garnered initial approval based on biomarkers,
the programs have been substantial in order to prove
clinical outcomes (2). It is worth noting that the reg-
ulatory approach to targeted therapy within CV dis-
ease has been similar to other diseases as witnessed
by the rapid approval of PCSK-9 inhibitors for familial
hypercholesterolemia. Within the cardiorenal port-
folio where there is clearly an unmet need or where
available therapy carries risks, biomarkers have been
accepted—for example, electrolyte disturbances or
glomerular ﬁltration rate—with less qualifying evi-
dence than we have for blood pressure and LDL, and
very large trial sizes for individual drug development
programs have not been required.
For post-myocardial infarction/heart failure
development, the clinical outcomes are tangible with
clear evidence of life-saving effects from a number of
available therapies, and the landscape is littered with
bones of development programs whose effects on
biomarkers turned out much better than did effects
on those clinical outcomes (9,10). In addition, it is
generally the case that a new therapy must be studied
on top of “standard medical therapy,” typically
guideline-directed therapy which has proven very
effective (11–16). These factors also contribute to large
development programs being required. It is worth
noting that for epidemic diseases, a modest treatment
effect spread across millions of patients can have a
profound beneﬁt for the public health, but this same
concept means that a modest detrimental effect can
cause signiﬁcant harm to individuals and overall
population health.
The empirical ﬁndings of this study raise inter-
esting issues about the future of drug development.
The steady attrition of molecules in each of the main
phases of development reminds us of the need to
understand better how to predict likely efﬁcacy and
toxicity. The continuing attrition in Phase 3 raises the
issue of whether Phase 2 trials could be better
designed to inform Phase 3 studies, ensuring that the
mechanism and dosing are well deﬁned, as well as
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311speciﬁc subgroups identiﬁed which may derive the
most beneﬁt from treatment to ensure the highest
chance of success in Phase 3—or how often unwar-
ranted optimism drives development following
nominally failed Phase 2 studies. One interesting
point is that the failure rate in CV disease does not
appear to be higher than in other diseases, so perhaps
it is not the “uncertainty” that is an issue, but rather
the fact that the evidentiary standard requires large,
global trials that is holding back investment. Several
other recent papers have found that CV drugs are no
more likely to fail during or after Phase I than other
disease areas (17).
Another challenge is the complex clinical manage-
ment of comorbid conditions. It is difﬁcult to separate
new CV targets without the overlap of existing thera-
pies on those pathways, or to distinguish speciﬁc CV
targets from comorbid inﬂuences. In this regard, it is
encouraging to see an increase in developing therapies
with novel biological pathways. Oncology is beginning
to enter a similar phase in which the combination of
multiple targeted therapies and immunotherapy raises
concern that stand-alone therapy is not a good
approach to either practice and that clinical trials of
stand-alone therapies may not provide information
needed to appropriately label drugs for use in an
increasingly complex clinical environment.
Recent regulatory science publications have
pointed out that drug development typically follows
new science that unveils molecular targets, so that
continued deep basic research in CV disease is crit-
ical. On the clinical research front, research should
continue to focus on clinically meaningful endpoints
and development of methods to measure them in a
scalable, less expensive fashion so that the eviden-
tiary standard can be met with a reasonable invest-
ment. As our ability to access information continues
to evolve, we can improve efﬁciency when large
sample sizes are needed by using information alreadycollected in electronic medical records, registries, and
medical billing claims to generate evidence which
may lead to the validation of such endpoints.
The combination of deeper molecular science and
enhanced, more efﬁcient, evidence generation may
make it possible to discover markers that correlate
with clinically meaningful improvements and novel
targets, and more importantly, fulﬁll criteria for sur-
rogacy—a change in the marker reliably predicting a
difference in clinically meaningful outcomes. These
advances may also allow use of multiple data ele-
ments to support a systems biology approach to
treating patients, so that perhaps more targeted pa-
tient cohorts may be recognized for targeted therapy
rather than casting a broad net for a therapy that may
work in a smaller subset.
The clinical, scientiﬁc, and economic foci of drug
development for targeted therapies for diseases
affecting smaller populations have led to more rela-
tive investment in these areas than in CV disease drug
development. We have several options to consider if
more investment is considered to be an important
goal in CV disease because of its enormous global toll.
Because drug development follows science,
continued investment in the basic biology of CV dis-
ease is needed, and because large populations are
impacted, attention to improved efﬁciency of the
evidence generation system will be needed to
generate needed sample sizes for deﬁnitive trials at a
lower cost. Finally, involving the full community
including industry, the National Institutes of Health,
academic experts, funding agencies, regulators,
practitioners, and patients will be an important step
in strengthening the science and advancing the ﬁeld.
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